Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (740 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Repetitive nucleic acid sequences that are principal components of the archaeal and bacterial crispr-cas systems, which function as adaptive antiviral defense systems.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Clustered Regularly Interspaced Short Palindromic Repeat; CRISPR Elements; CRISPR Element; Element, CRISPR; Elements, CRISPR; CRISPR Sequences; CRISPR Sequence; Sequence, CRISPR.
Where it fits in the MeSH classification
- Broader topics
- Inverted Repeat Sequences; Tandem Repeat Sequences
- See also
- CRISPR-Associated Proteins
Related concepts
Research landscape
PubMed indexes 6,684 records tagged with the MeSH heading “Clustered Regularly Interspaced Short Palindromic Repeats” (counts retrieved 2026-10-29). 3,474 of them (52.0%) were published from 2020 onward, and the busiest period so far is 2020 onward with 3,474 records.
Reviews account for 1,097 records (16.4%) and meta-analyses for 9. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 0 |
| 2000-2009 | 0 |
| 2010-2019 | 3,278 |
| 2020 onward | 3,474 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 1,097 | 16.4% |
| Meta-analyses | 9 | 0.1% |
| Randomized controlled trials | 0 | 0.0% |
Method: PubMed query "Clustered Regularly Interspaced Short Palindromic Repeats"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in molecular biology
Molecular biology establishes mechanisms through controlled experiments, often in simplified systems such as purified proteins, cultured cells or model organisms. Such work can show what is possible in a defined system, but whether a pathway matters in a whole organism or in human disease needs further evidence. Check the experimental system, whether findings were reproduced by independent groups, and whether the authors tested the mechanism directly or inferred it from correlation.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors | 2022 | Research article Design not recorded in structured metadata | 172 | cc0 PMID 36576240 · DOI · PMC9829409 |
| Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer | 2023 | Research article Design not recorded in structured metadata | 159 | cc by PMID 37968405 · DOI · PMC10700132 |
| Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits | 2025 | Research article Design not recorded in structured metadata | 108 | cc by PMID 40081369 · DOI · PMC12135205 |
| CRISPR-GPT for agentic automation of gene-editing experiments | 2026 | Research article Design not recorded in structured metadata | 64 | cc by PMID 40738974 · DOI · PMC12920143 |
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors [1]
Abstract reading summary — source excerpts
- Opening excerpt
- CRISPR interference (CRISPRi) enables programmable, reversible, and titratable repression of gene expression (knockdown) in mammalian cells.
- Closing excerpt
- Our results and publicly available reagents establish best practices for CRISPRi genetic screening.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (168 words)
CRISPR interference (CRISPRi) enables programmable, reversible, and titratable repression of gene expression (knockdown) in mammalian cells. Initial CRISPRi-mediated genetic screens have showcased the potential to address basic questions in cell biology, genetics, and biotechnology, but wider deployment of CRISPRi screening has been constrained by the large size of single guide RNA (sgRNA) libraries and challenges in generating cell models with consistent CRISPRi-mediated knockdown. Here, we present next-generation CRISPRi sgRNA libraries and effector expression constructs that enable strong and consistent knockdown across mammalian cell models. First, we combine empirical sgRNA selection with a dual-sgRNA library design to generate an ultra-compact (1-3 elements per gene), highly active CRISPRi sgRNA library. Next, we compare CRISPRi effectors to show that the recently published Zim3-dCas9 provides an excellent balance between strong on-target knockdown and minimal non-specific effects on cell growth or the transcriptome. Finally, we engineer a suite of cell lines with stable expression of Zim3-dCas9 and robust on-target knockdown. Our results and publicly available reagents establish best practices for CRISPRi genetic screening.
Abstract reproduced from the open-access article under the recorded cc0 licence; © the authors. PMID 36576240 · DOI · PMC9829409
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [2]
Abstract reading summary — source excerpts
- Opening excerpt
- CD8+ cytotoxic T cells (CTLs) orchestrate antitumour immunity and exhibit inherent heterogeneity1,2, with precursor exhausted T (Tpex) cells but not terminally exhausted T (Tex) cells capable of responding to existing immunotherapies3-7.
- Closing excerpt
- Collectively, our study reveals that promoting the exit from quiescence of Tpex cells and enriching the proliferative Tex cell state act as key modalities for antitumour effects and provides a systemic framework to integrate cell fate regulomes and reprogrammable functional determinants for cancer immunity.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (237 words)
CD8+ cytotoxic T cells (CTLs) orchestrate antitumour immunity and exhibit inherent heterogeneity1,2, with precursor exhausted T (Tpex) cells but not terminally exhausted T (Tex) cells capable of responding to existing immunotherapies3-7. The gene regulatory network that underlies CTL differentiation and whether Tex cell responses can be functionally reinvigorated are incompletely understood. Here we systematically mapped causal gene regulatory networks using single-cell CRISPR screens in vivo and discovered checkpoints for CTL differentiation. First, the exit from quiescence of Tpex cells initiated successive differentiation into intermediate Tex cells. This process is differentially regulated by IKAROS and ETS1, the deficiencies of which dampened and increased mTORC1-associated metabolic activities, respectively. IKAROS-deficient cells accumulated as a metabolically quiescent Tpex cell population with limited differentiation potential following immune checkpoint blockade (ICB). Conversely, targeting ETS1 improved antitumour immunity and ICB efficacy by boosting differentiation of Tpex to intermediate Tex cells and metabolic rewiring. Mechanistically, TCF-1 and BATF are the targets for IKAROS and ETS1, respectively. Second, the RBPJ-IRF1 axis promoted differentiation of intermediate Tex to terminal Tex cells. Accordingly, targeting RBPJ enhanced functional and epigenetic reprogramming of Tex cells towards the proliferative state and improved therapeutic effects and ICB efficacy. Collectively, our study reveals that promoting the exit from quiescence of Tpex cells and enriching the proliferative Tex cell state act as key modalities for antitumour effects and provides a systemic framework to integrate cell fate regulomes and reprogrammable functional determinants for cancer immunity.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37968405 · DOI · PMC10700132
Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Pooled optical screens have enabled the study of cellular interactions, morphology, or dynamics at massive scale, but they have not yet leveraged the power of highly plexed single-cell resolved transcriptomic readouts to inform molecular pathways.
- Closing excerpt
- Perturb-FISH is thus a general method for studying the genetic and molecular associations of spatial and functional biology at single-cell resolution.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (163 words)
Pooled optical screens have enabled the study of cellular interactions, morphology, or dynamics at massive scale, but they have not yet leveraged the power of highly plexed single-cell resolved transcriptomic readouts to inform molecular pathways. Here, we present a combination of imaging spatial transcriptomics with parallel optical detection of in situ amplified guide RNAs (Perturb-FISH). Perturb-FISH recovers intracellular effects that are consistent with single-cell RNA-sequencing-based readouts of perturbation effects (Perturb-seq) in a screen of lipopolysaccharide response in cultured monocytes, and it uncovers intercellular and density-dependent regulation of the innate immune response. Similarly, in three-dimensional xenograft models, Perturb-FISH identifies tumor-immune interactions altered by genetic knockout. When paired with a functional readout in a separate screen of autism spectrum disorder risk genes in human-induced pluripotent stem cell (hIPSC) astrocytes, Perturb-FISH shows common calcium activity phenotypes and their associated genetic interactions and dysregulated molecular pathways. Perturb-FISH is thus a general method for studying the genetic and molecular associations of spatial and functional biology at single-cell resolution.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40081369 · DOI · PMC12135205
CRISPR-GPT for agentic automation of gene-editing experiments [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Performing effective gene-editing experiments requires a deep understanding of both the CRISPR technology and the biological system involved.
- Closing excerpt
- CRISPR-GPT enables fully AI-guided gene-editing experiment design and analysis across different modalities, validating its effectiveness as an AI co-pilot in genome engineering.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (172 words)
Performing effective gene-editing experiments requires a deep understanding of both the CRISPR technology and the biological system involved. Meanwhile, despite their versatility and promise, large language models (LLMs) often lack domain-specific knowledge and struggle to accurately solve biological design problems. We present CRISPR-GPT, an LLM agent system to automate and enhance CRISPR-based gene-editing design and data analysis. CRISPR-GPT leverages the reasoning capabilities of LLMs for complex task decomposition, decision-making and interactive human-artificial intelligence (AI) collaboration. This system incorporates domain expertise, retrieval techniques, external tools and a specialized LLM fine tuned with open-forum discussions among scientists. CRISPR-GPT assists users in selecting CRISPR systems, experiment planning, designing guide RNAs, choosing delivery methods, drafting protocols, designing assays and analysing data. We showcase the potential of CRISPR-GPT by knocking out four genes with CRISPR-Cas12a in a human lung adenocarcinoma cell line and epigenetically activating two genes using CRISPR-dCas9 in a human melanoma cell line. CRISPR-GPT enables fully AI-guided gene-editing experiment design and analysis across different modalities, validating its effectiveness as an AI co-pilot in genome engineering.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40738974 · DOI · PMC12920143
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article CRISPR-Cas9 Structures and Mechanisms [5]
- Research article The next generation of CRISPR-Cas technologies and applications [6]
- Research article Delivering CRISPR: a review of the challenges and approaches [7]
- Research article CRISPR/Cas Genome Editing and Precision Plant Breeding in Agriculture [8]
- Research article CRISPR technology: A decade of genome editing is only the beginning [9]
- Research article Cornerstones of CRISPR-Cas in drug discovery and therapy [10]
References
- Replogle JM, Bonnar JL, Pogson AN, Liem CR, Maier NK, Ding Y, et al.. Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors. . 2022. PMID 36576240 · DOI · PMC9829409
- Zhou P, Shi H, Huang H, Sun X, Yuan S, Chapman NM, et al.. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. . 2023. PMID 37968405 · DOI · PMC10700132
- Binan L, Jiang A, Danquah SA, Valakh V, Simonton B, Bezney J, et al.. Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits. . 2025. PMID 40081369 · DOI · PMC12135205
- Qu Y, Huang K, Yin M, Zhan K, Liu D, Yin D, et al.. CRISPR-GPT for agentic automation of gene-editing experiments. . 2026. PMID 40738974 · DOI · PMC12920143
- Jiang F, Doudna JA. CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys. 2017. PMID 28375731 · DOI
- Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019. PMID 31147612 · DOI · PMC7079207
- Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018. PMID 29801422 · DOI · PMC6058482
- Chen K, Wang Y, Zhang R, Zhang H, Gao C. CRISPR/Cas Genome Editing and Precision Plant Breeding in Agriculture. Annu Rev Plant Biol. 2019. PMID 30835493 · DOI
- Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Science. 2023. PMID 36656942 · DOI
- Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017. PMID 28008168 · DOI · PMC5459481
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.